Women with axSpA: Navigating the childbearing years
Prof. Peter C Taylor considers aspects of axSpA that need to be proactively addressed when managing women of childbearing age – pre-pregnancy, during pregnancy, intrapartum, post-pregnancy and while breastfeeding.1/1 Leave Feedback
Overview & Learning Objectives
In this activity, rheumatology expert Prof. Peter C Taylor considers aspects of axSpA that need to be proactively addressed when managing women of childbearing age – pre-pregnancy, during pregnancy, intrapartum, post-pregnancy and while breastfeeding.
This activity has been designed to meet the educational needs of rheumatology specialists involved in the management of axSpA in women of childbearing age.
After watching this activity, participants should be better able to:
- Recognize that prevalence, diagnosis, disease progression and treatment efficacy differ between men and women with axSpA
- Evaluate the unique challenges that exist for women of childbearing age with axSpA
- Discuss optimal treatment strategies for women of childbearing age with axSpA
Faculty & Disclosures
Prof. Peter C Taylor
University of Oxford, Oxford, UK
Peter C Taylor holds the Norman Collison chair of musculoskeletal sciences at the University of Oxford and is a Fellow of St. Peter’s College. He is Head of Clinical Sciences at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences. He studied pre-clinical medical sciences at Gonville and Caius College at the University of Cambridge and his first degree was in Physiology. He subsequently studied clinical medicine at the University of Oxford and was awarded a PhD degree from the University of London for research on pathogenesis of arthritis. Prof. Taylor has specialist clinical interests in inflammatory arthritis. He has over 25 years of experience in clinical trial design in studies of biologic and small molecular therapies in rheumatoid arthritis and ankylosing spondylitis. In experimental medicine studies, Prof. Taylor employs targeted therapies as probes of pathogenesis to investigate the in vivo biology of the target in the pathobiology of the disease phenotype under investigation.
Prof. Peter C Taylor discloses: Research grants from Celgene, Eli Lilly, Galapagos and Gilead. Consultation fees from AbbVie, Biogen, Bristol Myers Squibb, Eli Lilly, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Nordic Pharma, Pfizer, Roche, Sanofi and UCB.